Antifungal Treatment for Suspected Fungal Meningitis in Pregnancy

Critical Treatment Principles in First Trimester

The American College of Obstetricians and Gynecologists and the Infectious Diseases Society of America recommend intravenous amphotericin B as the treatment of choice for all systemic fungal infections during pregnancy, particularly in the first trimester, due to its successful use without obvious fetal harm 1, 3
Azole antifungals, such as fluconazole, voriconazole, and itraconazole, must be strictly avoided during the first trimester due to documented teratogenic effects, including craniosynostosis, characteristic facies, digital synostosis, and limb contractures ("fluconazole embryopathy") 1, 2
Micafungin, an echinocandin, has no activity against Cryptococcus or other common causes of fungal meningitis and would be ineffective 4, 5

The Infectious Diseases Society of America recommends amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV as the initial treatment for suspected cryptococcal or other fungal meningitis, with liposomal amphotericin B at 3-6 mg/kg/day as an alternative with less nephrotoxicity 4, 5
Flucytosine 100 mg/kg/day (divided into 4 doses) should be added to amphotericin B if available, as combination therapy has superior efficacy for cryptococcal meningitis 4, 5

Elevated intracranial pressure (ICP) is a critical determinant of outcome, and opening pressure should be measured immediately with lumbar puncture 4, 5
Therapeutic lumbar punctures should be performed daily to reduce pressure by 50% or to normal levels (≤20 cm H₂O) if CSF pressure exceeds 25 cm H₂O 4, 5
Mannitol has no proven benefit and acetazolamide should be avoided for ICP control 4, 5

The Infectious Diseases Society of America recommends continuing amphotericin B (with or without flucytosine) for at least 2 weeks during the first trimester, with monitoring for clinical improvement, CSF sterilization, and resolution of symptoms 4, 5, 6
After completing the first trimester, transition to oral fluconazole 400-800 mg daily can be considered for consolidation therapy, as the teratogenic risk is primarily in the first trimester 1, 3

The American College of Obstetricians and Gynecologists and the Infectious Diseases Society of America recommend never prescribing oral azole antifungals during the first trimester, even if the patient appears stable 1, 2
Failure to manage elevated ICP is associated with increased mortality, requiring aggressive CSF drainage, not just antifungal therapy 4, 5